OptimizeRx (NASDAQ:OPRX) PT Lowered to $11.00

OptimizeRx (NASDAQ:OPRX) had its target price lowered by analysts at Barclays from $15.00 to $11.00 in a research note issued on Monday, Benzinga reports. The firm currently has an “equal weight” rating on the stock. Barclays‘s price target points to a potential upside of 27.17% from the company’s previous close.

OPRX has been the topic of several other reports. JMP Securities restated a “market outperform” rating and issued a $16.00 price objective on shares of OptimizeRx in a research report on Friday, June 21st. B. Riley assumed coverage on shares of OptimizeRx in a report on Thursday, July 25th. They issued a “buy” rating and a $18.50 target price on the stock. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $13.00 price target on shares of OptimizeRx in a report on Wednesday, May 15th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat.com, OptimizeRx presently has an average rating of “Moderate Buy” and a consensus target price of $15.50.

OptimizeRx Stock Performance

Shares of OPRX opened at $8.65 on Monday. OptimizeRx has a 12-month low of $6.92 and a 12-month high of $16.65. The stock has a market cap of $158.04 million, a P/E ratio of -8.48 and a beta of 1.26. The company has a current ratio of 2.88, a quick ratio of 2.88 and a debt-to-equity ratio of 0.26. The company has a 50-day moving average of $10.26 and a two-hundred day moving average of $11.85.

OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.16). The company had revenue of $19.69 million for the quarter, compared to analyst estimates of $18.66 million. OptimizeRx had a negative return on equity of 6.96% and a negative net margin of 23.10%. During the same quarter in the prior year, the firm earned ($0.34) earnings per share. As a group, research analysts predict that OptimizeRx will post -0.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Summit Securities Group LLC purchased a new stake in OptimizeRx in the second quarter valued at approximately $25,000. Nisa Investment Advisors LLC grew its stake in shares of OptimizeRx by 215.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company’s stock valued at $31,000 after buying an additional 1,462 shares during the period. Cetera Trust Company N.A acquired a new stake in shares of OptimizeRx during the 4th quarter worth $77,000. Connors Investor Services Inc. raised its position in shares of OptimizeRx by 15.1% in the 2nd quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock worth $191,000 after buying an additional 2,500 shares during the period. Finally, Hillsdale Investment Management Inc. purchased a new stake in OptimizeRx during the fourth quarter valued at about $225,000. Institutional investors and hedge funds own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.